Related references
Note: Only part of the references are listed.Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model
Carleen Cullinane et al.
MOLECULAR CANCER THERAPEUTICS (2010)
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis
Ricardo T. Paniagua et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro
Stephen J. Blake et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells
Oliver Dienz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway
Fumitaka Terabe et al.
MODERN RHEUMATOLOGY (2009)
Imatinib and beyond-exploring the full potential of targeted therapy for CML
Alfonso Quintas-Cardama et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis
Asuka Inoue et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase
Keiichi Iwanami et al.
ARTHRITIS AND RHEUMATISM (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis
Isao Matsumoto et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis
N. Brownlow et al.
LEUKEMIA (2008)
T-cell-targeted therapies in rheumatoid arthritis
CM Weyand et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice
D Schubert et al.
JOURNAL OF IMMUNOLOGY (2004)
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
K Cwynarski et al.
LEUKEMIA (2004)
Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
K Miyachi et al.
CLINICAL RHEUMATOLOGY (2003)
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders
I Matsumoto et al.
ARTHRITIS AND RHEUMATISM (2003)
Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases
KK Eklund et al.
ANNALS OF MEDICINE (2003)
Share Paper
